Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average recommendation of "Buy" from nine analysts, with eight giving a buy and one a strong buy recommendation.
• The average target price set by analysts for CMPX is $13.8750, with notable increases from Guggenheim and D. Boral Capital suggesting future growth potential.
• As of now, Compass Therapeutics has a market capitalization of $467.40 million and has been trading between a 52-week low of $1.27 and a high of $4.08.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been given an average recommendation of "Buy" by the nine analysts that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $13.8750.

CMPX has been the topic of a number of analyst reports. Guggenheim upped their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. D. Boral Capital reissued a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 target price on the stock in a research note on Tuesday, July 1st.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $3.38 on Wednesday. The company has a 50-day simple moving average of $3.20 and a 200-day simple moving average of $2.53. The firm has a market capitalization of $467.40 million, a P/E ratio of -7.51 and a beta of 1.50. Compass Therapeutics has a 52 week low of $1.27 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Large investors have recently added to or reduced their stakes in the company. Creative Planning bought a new stake in Compass Therapeutics during the second quarter worth about $30,000. Strs Ohio bought a new stake in Compass Therapeutics during the first quarter worth about $34,000. BNP Paribas Financial Markets bought a new stake in Compass Therapeutics during the fourth quarter worth about $27,000. Marex Group plc bought a new stake in Compass Therapeutics during the second quarter worth about $61,000. Finally, Birchview Capital LP bought a new stake in Compass Therapeutics during the first quarter worth about $46,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.